Cochrane · systematic review · CD004388
Human recombinant protein C for severe sepsis and septic shock in adult and paediatric patients
Martí‐Carvajal, AJ, Solà, I, Gluud, C, et al. · Cochrane Database of Systematic Reviews · 2012 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 100%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 3 versionsHuman recombinant activated protein C compared to placebo for severe sepsis or septic shock
Population: patients with severe sepsis or septic shock
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
28‐Day all‐cause mortality (adult and paediatric patients) Human recombinant activated protein C vs placebo | RR 1 [0.86, 1.16] | 6 studies · 6781 participants | Moderate |
In‐hospital mortality (adult and paediatric patients) Human recombinant activated protein C vs placebo | RR 1.04 [0.94, 1.15] | 5 studies · 4307 participants | Moderate |
Serious bleeding events in adult and paediatric patients (days 0 to 28) Human recombinant activated protein C vs placebo | RR 1.45 [1.08, 1.94] | 6 studies · 6767 participants | Moderate |
Serious adverse events (adult and paediatric patients) Human recombinant activated protein C vs placebo | RR 1.04 [0.92, 1.18] | 5 studies · 6636 participants | Moderate |